Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.72 |
| ▸ | ABL1 | P00519 | 10/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.70 |
| ▸ | KDR | P35968 | 2/20 | 0.70 |
| ▸ | KIT | P10721 | 5/20 | 0.70 |
| ▸ | SRC | P12931 | 4/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.66 |
| ▸ | FLT1 | P17948 | 1/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.66 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21730605 | 0.93 | KIT (0.71) | RETABL1FGFR1KDRKIT | |
| SCHEMBL21730607 | 0.93 | RET (0.71) | RETABL1FGFR1KDRKIT | |
| SCHEMBL21730615 | 0.93 | RET (0.71) | RETABL1FGFR1KDRKIT | |
| SCHEMBL21730701 | 0.92 | RET (0.69) | RETABL1FGFR1KDRKIT | |
| SCHEMBL21730634 | 0.91 | RET (0.68) | RETABL1FGFR1KDRKIT | |
| SCHEMBL21730614 | 0.91 | RET (0.68) | RETABL1FGFR1KDRKIT | |
| SCHEMBL21730612 | 0.91 | ABL1 (0.72) | RETABL1FGFR1KDRKIT | |
| SCHEMBL21730625 | 0.91 | RET (0.68) | RETABL1FGFR1KDRKIT | |
| SCHEMBL21730610 | 0.91 | RET (0.68) | RETABL1FGFR1KDRKIT | |
| SCHEMBL21730616 | 0.91 | RET (0.68) | RETABL1FGFR1KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988456-B2 | O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200055838-A1 | O-AMINOHETEROARYL ALKYNYL-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055838-A1 | O-AMINOHETEROARYL ALKYNYL-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | FGFR3, FGFR1, FGFR2 | RET 9/4885ABL1 122/4885FGFR1 2/4885 |
| US-10988456-B2 | O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof | FGFR3, FGFR1, FGFR2 | RET 9/4885ABL1 122/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.